They were pioneers in identifying NPRC as a promising candidate for prostate cancer imaging applications, expanded application of the natriuretic peptide receptor in tumor diagnosis, and developed a nanoprobe targeting the NPRC receptor, which was demonstrated to be highly efficient and specific in PET imaging of prostate cancer through precise molecular design and in vivo validation, providing a new strategy for clinical translation. The gene discussed is NPR3; the disease is neoplasm.